NCT04563962: C-MAX

Contingency Management for PrEP Adherence and/or Methamphetamine Use

Completed NA Last updated 29 September 2021

What this trial tests

NA trial testing Contingency Management-ART in Methamphetamine-dependence in 20 participants. Completed in 31 August 2021.

Timeline

15 March 2021

Primary endpoint
31 August 2021

31 August 2021

Quick facts

Lead sponsor	University of California, Los Angeles
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	20
Start date	15 March 2021
Primary completion	31 August 2021
Estimated completion	31 August 2021
Sites	1 location across United States

Drugs / interventions tested

• Contingency Management-ART
• Contingency Management-Methamphetamine

Conditions studied

• Methamphetamine-dependence — all drugs for Methamphetamine-dependence →
• HIV-1-infection — all drugs for HIV-1-infection →

Sponsor

University of California, Los Angeles

Who can join

18 and older, male only, with Methamphetamine-dependence or HIV-1-infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Use of crystal methamphetamine (MA) leads to changes in sexual risk behavior, adherence to HIV prevention tools, immune response to infection, and tissue inflammation that collectively increase risk for HIV transmission among MA-using men who have sex with men (MSM), their sexual partners, and their networks. Contingency Management (CM) offers a behavioral modification tool helpful for reducing frequency of MA use, but the effects of CM on the behavioral and biological factors that promote HIV transmission in MSM networks have only been partially evaluated. The intersection of substance use, sexual risk behavior, and HIV transmission in MSM networks presents a critical problem for contemporary HIV prevention as HIV-uninfected MSM who use MA have a 16%-33% greater risk for HIV infection, while only approximately 50% of HIV-infected MA-using MSM achieve and maintain an undetectable viral load. The investigators propose to compare two different CM models to integrate substance use treatment with HIV prevention among MA-using MSM: 1) Traditional CM targeted to MA abstinence and 2) Allternative CM based on ARV adherence.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Contingency Management for Integrated Harm Reduction Among Men Who Have Sex with Men Who Use Methamphetamine in Los Angeles: A Pilot Assessment.
   Blair CS, Gandhi M, Shoptaw S, Blades C, et al · · 2023 · cited 5× · PMID 36414775 · DOI 10.1007/s10461-022-03929-6